Depressionen: Remission durch Psilocybin bei laufender SSRI-Therapie
Fortschritte der Neurologie · Psychiatrie April 1, 2024 DOI: 10.1055/a-2254-0360 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Psilocybin Depression |
| Keywords | Hallucinogen |
| Key findings | Psilocybin can enhance SSRI therapy for depression. |
Abstract
Psilocybin ist ein Indolalkaloid aus der Gruppe der Tryptamine und wird zur Behandlung behandlungsresistenter Depressionen (TRD) untersucht. Da die Einnahme von Antidepressiva die psychedelische Wirkung von Psilocybin potenziell verändern kann, werden diese vor Studienbeginn regelhaft ausgeschlichen. Goodwin et al. dagegen wollten prüfen, ob Psilocybin eine SSRI-Therapie bereichern kann, und kommen in ihrer Studie zu einem positiven Ergebnis.
Comparable studies
Other randomized controlled trials on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety | 2016 | Randomized controlled trial | n = 51 |
| Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression | 2016 | Double-blind, placebo-controlled, crossover trial | n = 29 |
| Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression | 2021 | Randomized controlled trial | |
| Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... | 2020 | Randomized controlled trial | n = 24 |
| Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. Adults with treatment-resistant depression | 2022 | Phase 2 double-blind randomized controlled trial | n = 233 |